1. Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study 
Hiroshi Okamoto, Masatsugu Hori, Masunori Matsuzaki, Hiroyuki Tsutsui, Tsutomu Yamazaki, Ryozo Nagai, Tsutomu Yoshikawa, Yasushi Fujio, Shinpei Nonen, Junichi Azuma, Tohru Izumi, Yasuo Ohashi, Akira Kitabatake 
International Journal of Cardiology 
Volume 164, Issue 2, Pages (April 2013)
DOI: /j.ijcard
Copyright © 2012 Elsevier Ireland Ltd Terms and Conditions

2. Fig. 1
Study protocol. The mean up-titration period (from the initiation of carvedilol to a fixed-dose period week 0) was 52.9days. NYHA, New York Heart Association, SAS, specific activity scale; SBP, systolic blood pressure; and BNP, brain natriuretic peptide.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2012 Elsevier Ireland Ltd Terms and Conditions

3. Fig. 2
J-CHF study profile. The patient flow chart shows that no patients (pts.) were lost to follow-up.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2012 Elsevier Ireland Ltd Terms and Conditions

4. Fig. 3
Changes in LVEF. The mean LVEF (left ventricular ejection fraction) from the initiation of carvedilol to the fixed-dose period of weeks 24 and 48 increased without a dose–response relationship. *P<0.05 versus the observation period (OP). Values represent the mean±CI.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2012 Elsevier Ireland Ltd Terms and Conditions

5. Fig. 4
Kaplan–Meier estimate for primary endpoint. The primary endpoint occurred in 74 patients during the mean 3-year follow-up period. No significant between-group differences for the primary endpoint were found.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2012 Elsevier Ireland Ltd Terms and Conditions

6. Fig. 5
A and B. Kaplan–Meier estimates for the primary endpoints ∆BNP log and ∆HR. The Kaplan–Meier plots for the primary endpoints by tertiles of ∆BNP log and ∆HR. ∆, change; BNP, brain natriuretic peptide; and HR, heart rate.
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2012 Elsevier Ireland Ltd Terms and Conditions

7. Fig. 6
Association between OPN G-156del polymorphism and event-free survival. Solid line, del homozygote and broken line, G allele carrier. The two curves were significantly different according to the Wilcoxon test (P=0.030).
International Journal of Cardiology  , DOI: ( /j.ijcard )
Copyright © 2012 Elsevier Ireland Ltd Terms and Conditions